Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Ephedrine Sulfate Injection USP, 50 mg/mL single-dose vials, the company announced through an exchange filing.
Ephedrine Sulfate Injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara (India).
Ephedrine Sulfate Injection USP, 50 mg/mL had annual sales of USD 52 mn in the United States.
The group now has 368 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
This 114-Year-Old Becomes Japan’s Oldest Living Person: Meet Shigeko Kagawa, Olympic Torchbearer & Retired Doctor
Uttarakhand CM Pushkar Singh Dhami Congratulates PM Modi As 'Pariksha Pe Charcha 2025' Sets Guinness World Record With 3.53 Crore Registrations
Tata Capital IPO Gets Sebi Nod, Plans ₹2 Billion Offer With Fresh Issue & OFS
WWE RAW: Becky Lynch Destroys Nikki Bella With Brutal John Cena Jab; Video
